StocksMedium•4 November 2026•
1 min read
GRAIL Galleri Revenue Rises 14% as FDA Advisory Committee Backs Cancer Test
Key Facts
1Galleri test revenue grew 14% year-over-year to $37.3 million in the third quarter.
2An FDA Advisory Committee voted in favor of approving GRAIL's Galleri multi-cancer early detection test.
3Galleri test volume increased approximately 24% to more than 56,000 units in Q3.
GRAIL reported that Galleri test revenue grew 14% year-over-year to $37.3 million in the third quarter of 2026. PR Newswire reported that an FDA Advisory Committee voted in favor of approving the company's Galleri multi-cancer early detection test. Galleri test volume also increased approximately 24% to more than 56,000 units during the quarter.
GRAL closed at $139.44 on November 3, 2026, with the stock trading between a low of $136.66 and a high of $144.23 during that session. The financial growth was supported by rising demand for the company's primary diagnostic product, while the favorable advisory committee vote provides a significant regulatory tailwind.